Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in 2025.

Various PD-1 and PD-L1 checkpoint inhibitors have been approved by U.S. regulators including blockbuster drugs Keytruda, Imfinzi, and Opdivo to treat different types of cancer. But that hasn’t stopped ...

The month of December 2024 saw a variety of biotech deals take place to advance therapies across different stages in ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

From AI to gene therapy, we reached out to industry experts to get their thoughts on the trends that will shape the biotech ...

Explore advances in von Willebrand disease treatment, including Star Therapeutics' VGA039, and other key players in the space ...

In the last year or so, there have been a number of indications that Saudi Arabia is setting itself up to become a global biotech hub. Over the next decade, it is expected to become a world leader in ...

A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes treatments that were approved last year or expected to debut this year and ...